We are aware of current issues with the ONS login. Please clear your device history/cache/cookies before attempting to log in. Thank you for your patience as we address this issue.

Oncology Drug Reference Sheet: Selinexor

By: Kristine B. LeFebvre, DNP, RN, NPD-BC, AOCN®

Published In: Voice

Publication Date: 2022-09-27

Description

After clinical trials demonstrated a 25% response rate in patients with multiple myeloma, selinexor (Xpovio^®) received initial, accelerated U.S. Food and Drug Administration approval in 2019.

View Article @ voice.ons.org

ONS Drug Education

Short summaries of newly approved oncology-related therapies or drugs with new indications.

View All Drug Education

Oncology Drug Reference Sheet: Selinexor

Description

ONS Drug Education

Related Topics